long8 - 龙8 - 龙八(国际)游戏官方网站

BIOQINGLAM
Leader in Transdermal Technology Research and Development and Solution for Soluble Microneedle Drug Delivery
BIOQINGLAM is a R&D-driven enterprise focusing on the R&D and industrialization of soluble microneedle drug delivery technology. Microneedle drug delivery technology is a complicated system engineering, involving MEMS, coating process, pharmaceutics, materials science, molecular biology, biochemistry, industrial engineering and other multidisciplinary and multi-field technologies. Application of the microneedle drug delivery technology requires strong capabilities of system integration. BIOQINGLAM team has 15 years of experience in project R&D and industrialization, and firmly practice the concept of the Design for Six Sigma (DFSS). In 2021, we got successes from the research of the soluble microneedles delivery for gene drugs in cooperation with our customers. At present, we are working with several listed pharmaceutical companies to develop microneedle-drugs, which include genetic vaccines, inactivated vaccines, proteins, polypeptide and chemical drugs. We combine closely research and development with industrialization, and have built and put into operation a GMP workshop dedicated to R&D of drugs. We provide technical outputs to our customers that can only be successfully industrialized.
"It starts small."
Leadership
  • Lin Jiang PhD.
    Founder/CEO/CSO

    Dr. Jiang is the founder of BioQingLam and the chief scientist of the R&D and industrialization of dissolvable MN TDDS. He granted his organic chemistry PhD from the Chinese Academy of Sciences.
    He has been continuously focusing on R&D and industrialization of this DDS for many years, granted over 40 invention patents.
    Dr. Jiang is a serial entrepreneur. Since his doctoral graduation in 2006, he has gained 6 complete experiences in the entire chain from R&D to industrialization, company governance, and ultimately achieving enterprise product sales.
    More
  • Venus Poon
    R&D Director

    Venus has more than ten years of experience in R&D, registration, and management of new drug formulations. She has served in multiple pharmaceuticals, responsible for the R&D, registration, and full lifecycle management for innovative drugs.
    Venus is very familiar with the requirements of both research and registration for innovative drugs, especially the regulatory requirements of IND and NDA.
    More
  • Olivia Chen
    VP RA head

    Olivia is an elite pharmacist. She is the 17th council member of GDPA, pharmaceutical engineering division, also a former CDE officer of China NMPA.
    Olivia has almost 20 years’ experience for regulatory, supervision, and review. She served in several Chinese biotech and public companies as a senior regulatory role, leading more than 30 global regulatory campaigns while some of those are collaborated with Top 20 pharma such as Novartis and AstraZeneca.
    More
  • XingYou Li
    Head of Quality System
    XingYou is an experienced engineer with more than 15 years’ laboratory experience and worked in the quality department of pharmaceutical enterprises for more than 20 years. He is 3 times involved in the establishment inspection laboratory and also building up GMP system for 3 times. He is very familiar with ISO 9001、CNAS、WHO-PQ、EU GMP and FDA GMP, a truly veteran of GMP auditing profession.
    XingYou has been engaged in the fields of biological products, traditional Chinese medicine preparations, chemical drug preparations, etc. for many years. Experienced quality research works for various forms of medicines, including but not limited to sterilized freeze-dried powder vials, liquid ambers, tablets, capsules, soft capsules, suspensions.
    More
  • Tie Chen
    Manufacture head
    Tie Chen Director of factory Tie has over ten years of production management experience in big pharmaceuticals, specializing in the production process and technical management of sterile injections. He believes in the philosophy of lean production and performance management, and is proficient in quality, safety, and cost control. He has organized GMP certification for newly built workshops multiple times, and has also organized and participated in the re certification of EU GMP and the coordination of audits for Top 20 pharmaceutical companies.
    More
Lin Jiang PhD.
Venus Poon
Olivia Chen
XingYou Li
Tie Chen
why microneedles
According to the latest professional literature, microneedle technology includes solid needle, hollow needle, coated needle, soluble microneedle and swelling needle. Based on its own research and development practices, BIOQINGLAM is optimistic about the application of soluble microneedle technology in drug delivery and diagnosis. Microneedle drug delivery technology is a practical science and a results-oriented technology.
  • Painless, less invasive, better compliance Height<450 μm, pricks stratum corneum only to reach lymphatic fluid in Epidermal layer, no contact with neurons or blood vessels in dermal, so patients won’t feel.
  • Less side effects, better safety Avoiding gastrointestinal side effects or the first pass effect of the liver. API still need to pass through several biological barriers
  • Easy to use, transport, and store Solid dosage form, good stability, no need for cold chain, Band-Aid kind of use
  • Various API can be delivered Peptide, Proteins(including anti-bodies), DNA/RNA, SMEs
PARTNERING
Microneedle drug delivery technology is a kind of dosage form technology and an innovative way of drug delivery. It is an innovative dosage form juxtaposed with tablets, capsules and injections. All drugs need a dosage form before they can be used by patients. In the past, drug developers could only choose conventional dosage forms such as tablets, capsules and injections. Now, soluble microneedle drug delivery technology has solved the industrialization problem, providing drug developers with a new dosage form.
MILESTONES
Sept 2024：Human IIT of MN semaglutide read out
Dec 2024：Construction of global 1st sterilized GMP MN plant finished, equipment deployment triggered, designed for 100,000 pieces/batch
Dec 2023： Obtained the recognition of "Specialized, Refined, Unique and New" small and medium-sized enterprises in Shenzhen
May 2023：Move into current location, expand lab to 3,000m2, R&D team up to 50.
Sept 2023：Dexmedetomidine delivered
Dec 2023：Monkey module of GLP-1 candidate semaglutide read out
Oct 2023：Recognized as a national high-tech enterprise
Jan 2022：DNA Vaccine successfully delivered, core tech verified
Dec 2022：C+A GMP like workshop established, 4,600 pieces/batch
July 2022： Angel round completed
友情链接: